FDA Fast Track Designation granted for Phentolamine Ophthalmic Solution 0.75% as treatment of significant chronic night ...

Opus Genetics (IRD) said that the FDA has granted Fast Track designation for Phentolamine Ophthalmic Solution 0.75%, reported ...

Opus Genetics (IRD) announced completion of enrollment in the VEGA-3 Phase 3 clinical trial evaluating Phentolamine Ophthalmic Solution 0.75% ...

First patient dosed in the pediatric cohort of the Phase 1/2 trial of OPGx-LCA5; initial data on the cohort anticipated by Q3 ...

Opus Genetics (IRD) announced that the first pediatric patient was dosed in its ongoing Phase 1/2 clinical trial evaluating OPGx-LCA5, its ...

Early intervention in pediatric LCA5 patients is particularly important, as it offers the best chance to preserve or restore visual function before the disease progresses," said George Magrath, M.D., ...

DURHAM, N.C. - Opus Genetics, Inc. (NASDAQ:IRD), a biotechnology firm focusing on gene therapies for inherited retinal diseases, has dosed the first pediatric patient in a Phase 1/2 clinical trial ...

(RTTNews) - Opus Genetics, Inc. (IRD), a clinical-stage ophthalmic biotechnology company, on Tuesday announced that the first pediatric patient has been dosed in its global Phase 1/2 clinical ...

10 Stocks to Sell NOW! 3 Stocks to DOUBLE This Year The 10 Best Stocks to Own in 2023 7 Stocks to Buy and Hold Forever 15.0% of Opus Genetics shares are held by institutional investors.

Opus Genetics is a clinical-stage ophthalmic biotechnology company developing gene therapies to treat patients with IRDs and other treatments for ophthalmic disorders. The pipeline includes adeno ...

Early intervention in pediatric LCA5 patients is particularly important, as it offers the best chance to preserve or restore visual function before the disease progresses,” said George Magrath, M.D., ...